| 7.45 0.06 (0.81%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.27 | 1-year : | 10.83 |
| Resists | First : | 7.94 | Second : | 9.27 |
| Pivot price | 7.29  |
|||
| Supports | First : | 6.77 | Second : | 6.05 |
| MAs | MA(5) : | 7.41 |
MA(20) : | 7.24 |
| MA(100) : | 6.52 |
MA(250) : | 4.47 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 61.4 |
D(3) : | 60.7 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 8.32 | Low : | 0.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STTK ] has closed below upper band by 34.0%. Bollinger Bands are 45.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.48 - 7.51 | 7.51 - 7.54 |
| Low: | 6.96 - 7 | 7 - 7.03 |
| Close: | 7.39 - 7.45 | 7.45 - 7.51 |
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Sat, 15 Aug 2026
Shattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street Zen - MarketBeat
Fri, 14 Aug 2026
T. Rowe Price Investment Management (STTK) reports 15.3% stake in Shattuck Labs - stocktitan.net
Thu, 13 Aug 2026
Several Insiders Invested In Shattuck Labs Flagging Positive News - webull.com
Thu, 13 Aug 2026
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade - Yahoo Finance
Tue, 11 Aug 2026
Is Shattuck Labs Inc (STTK) Overvalued Following Q2 Earnings Mis - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 4.851e+007 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 2,540 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.894e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 258.2 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -55 |
| EBITDA (p.s.) | -2.68468e+006 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 6.51 |
| Dividend | 0 |
| Forward Dividend | 7.8e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|